Sandra Naaman, Director of Medical Subspecialties at Rush University Medical Center, shared a post on LinkedIn:
“The 2025 ATA Guidelines for Differentiated Thyroid Cancer represents the most significant updated to thyroid cancer management in a decade – and last night, we brought them to life. I co-led a CME evening of expert presentations, covering everything from genomic risk, stratification, and surgical decision-making to systemic therapy and the long-term effects of treatments on survivors. The goal: equip clinicians with the tools to translate evidence into better, more personalized care.
This is the work! Thank you to our excellent Faculty and our engaged audience- and to the patient whose outcomes depend on us staying current and committing to excellence.”
Other articles from OncoDaily.
